Brief: Cytomx Therapeutics Reports First Quarter 2023 Financial Results And Provides Business Update
09/05/2023 23:07
Cytomx Therapeutics Inc CTMX.O :
* CYTOMX THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS
AND PROVIDES BUSINESS UPDATE
* CONTINUED PROGRESS IN PHASE 1 DOSE ESCALATION FOR CX-904
(EGFRXCD3)
* CYTOMX THERAPEUTICS - IND ENABLING ACTIVITIES ON TRACK FOR
FILINGS FOR CX-2051 (EPCAM-DIRECTED ADC) AND CX-801 (INTERFERON
ALPHA-2B) IN H2 OF 2023
* QTRLY LOSS PER SHARE $0.05
* Q1 EARNINGS PER SHARE VIEW $-0.11 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX4gT3nR
Further company coverage: CTMX.O
Recent news on CytomX Therapeutics
See all newsCytomX Q2 revenue misses, partly hurt by lower research activities in the Astellas collaboration
CytomX Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Cytomx Therapeutics Announces Appointment Of Charles Fuchs, M.D., M.P.H., To The Board Of Directors
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway